



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	402693	Defender-C
ARTG entry for	Medicine Listed	
Sponsor	Greal Labs Pty Ltd	
Postal Address	PO Box 193, Fitzroy, VIC, 3065 Australia	
ARTG Start Date	20/01/2023	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Defender-C

Product Type	Single Medicine Product	Effective Date	20/01/2023
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support collagen formation
Maintain/support collagen health
Relieve weariness/tiredness/fatigue/feeling of weakness
Maintain/support gum health
Maintain/support healthy teeth
Maintain/support connective tissue health
Aid/assist/helps connective tissue production/formation
Maintain/support bone health
Helps maintain/support joint cartilage health
Maintain/support healthy immune system function
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
Decrease/reduce/relieve common cold duration
Maintain/support skin health
Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Public Summary



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form Tablet, chewable

Route of Administration Oral

Visual Identification

Active Ingredients

ascorbic acid	500 mg
sodium ascorbate	565.68 mg
Equivalent: ascorbic acid	500 mg

Other Ingredients (Excipients)

- carmellose sodium
- Citrus bioflavonoids extract
- Flavour
- lecithin
- magnesium stearate
- maize starch
- maltodextrin
- Rice bran oil
- silicified microcrystalline cellulose
- silicon dioxide
- Siraitia grosvenorii
- stearic acid
- xylitol

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.